Bring Hope to Patients by Designing Innovative Treatments 

Basal cell carcinoma (BCC) is the most common type of skin cancer. In North America, 3.6 million cases are diagnosed each year. BCC results from the uncontrolled growth of skin cells, primarily in areas of the body that have been exposed to the sun for extended periods. Patients affected by BCC commonly develop tumors on the face, neck, scalp, and arms, which are areas that are often highly visible and cosmetically sensitive. Additionally, patients with BCC are at a higher risk of developing new or multiple lesions.

The standard treatment for BCC is surgical removal or excision. While non-surgical treatments exist, they are not indicated for all types of BCC and can lead to side effects. As a result, many patients undergo surgery, which may require extended procedural time, local wound care, and a recovery period. Cosmetic changes to the treated skin, including scarring or discoloration, may occur. Some patients require multiple procedures over time depending on disease recurrence or the number of lesions treated. This underscores continued interest in evaluating additional treatment approaches for patients with BCC.

Feldan Therapeutics is developing FLD-103, an investigational non-surgical approach to treat nodular BCC, the most common subtype of the disease. This treatment, injected directly into the tumor, is intended to selectively target BCC cells by disrupting an intracellular component involved in the pathophysiology of the disease, with the aim of preserving surrounding healthy tissue and supporting cosmetically favorable outcomes.

FLD-103 is currently being investigated in a Phase 1 clinical study to evaluate its safety, tolerability and exploratory efficacy.